Sex: U
Vaccine: COVID19
Symptoms: Nausea, Pyrexia, Vaccination site pain, Vomiting
Clinical narrative: Moderate malaise/feeling sick present with some interference with activity; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement); Mild fever (100.4 to 101.2 Degree F); Severe fatigue with significant interference with activity; Severe muscle pain significantly interfering with activity; Joint pain and no interference with activity; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; This spontaneous case was reported by a non-healthcare professional and describes the occurrence of MALAISE (Moderate malaise/feeling sick present with some interference with activity), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement)), PYREXIA (Mild fever (100.4 to 101.2 Degree F)) and FATIGUE (Severe fatigue with significant interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In January 2024, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In January 2024, the patient experienced MALAISE (Moderate malaise/feeling sick present with some interference with activity), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement)), PYREXIA (Mild fever (100.4 to 101.2 Degree F)), FATIGUE (Severe fatigue with significant interference with activity), MYALGIA (Severe muscle pain significantly interfering with activity), ARTHRALGIA (Joint pain and no interference with activity) and NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting). At the time of the report, MALAISE (Moderate malaise/feeling sick present with some interference with activity), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement)), PYREXIA (Mild fever (100.4 to 101.2 Degree F)), FATIGUE (Severe fatigue with significant interference with activity), MYALGIA (Severe muscle pain significantly interfering with activity), ARTHRALGIA (Joint pain and no interference with activity) and NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In January 2024, Body temperature: Mild fever (100.4 to 101.2 Degree F).         No concomitant medications were reported.  It was reported that worst pain, worst tenderness, highest fever, worst intensity of fatigue, worst intensity of feeling unwell, worst intensity of muscle pain, worst intensity of joint pain and worst level of nausea and/or vomiting experienced anytime during the 2 days after COVID-19 vaccination, which occurred on Sunday, 21- Jan-2024 and Monday, 22- Jan-2024.  No treatment medications were reported.